Dexrazoxane for Injection is indicated for reducing the incid ence and severity of cardiomyopathy associated with doxorubicin ad m inistration in wo men with metastatic breast cancer who have received a cu mulative doxorubicin dose of 300 mg / m 2 and who will c ontinue to receive doxor ubicin therapy to maintain tu mor control. Do not use with the initiat ion of doxorubicin therapy [see Warnings and Precautions.